Did you miss the boat for the monster Netflix gains that hit the tape on Wednesday? The "Mad Money" host has been blindsided by bad calls on analysts before, but not this time.
Two analysts nailed it perfectly, urging investors to buy ahead of the quarter.
"The work, done by John Blackledge at Cowen and Scott Devitt at Stifel, was exemplary and worth praising to the skies, because you had plenty of opportunity to act on their upgrades," said the "Mad Money" host.
Cowen had some intense research based on a survey of 1,000 U.S. citizens, which indicated that the original content available on Netflix caused users to spend more time using it. Thus, they were willing to pay more for the membership.
It also indicated that users were doing more binge watching of Netflix programming, indicating that the acceptance of higher membership fees could lead to higher profits down the road.
Read More Cramer's nod to Netflix—how they nailed it
So far this month, Cramer has been on a mission to find the hottest biotechs of 2015. While reviewing all of the top performers of last year, he has found one that not only doubled in value last year, but has a personal mission to find a life-saving cure.
John Crowley is the chairman and CEO of Amicus Therapeutics, and is also a father and Navy reservist that fought to raise money to become a biotech entrepreneur. He didn't do this just to make money, but he did it in an effort to save his two children from a rare condition called Pompe disease.
Wednesday celebrates the five year anniversary of the movie Extraordinary Measures, starring Brendan Frasier and Harrison Ford, which chronicled Crowley's devotion to saving his daughter's lives.
Pompe is a neuromuscular disease that can ultimately be fatal, even with enzyme replacement therapy. Amicus has a drug in phase 2 trials that leverages their advanced enzyme replacement chaperone platform.
"We got involved in biotech in the late 90's when two of our children were diagnosed with a rare genetic disease…at the time there was nothing," said Crowley "So we really focused as parents initially on what could we do to help drive science to a cure. That was our initial effort, and that led to the development to a first generation treatment that our kids have been on for more than a decade. It saved their lives."
Read MoreCramer: A hot biotech with a personal mission